Kusurinomadoguchi (5592) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Sep, 2025Executive summary
Consolidated revenue for Q1 FY2025 was ¥2,629 million, up 22.1% year-over-year, with operating profit at ¥382 million, down 16.5% year-over-year but up sequentially from the previous quarter.
Net income attributable to shareholders was ¥239 million, down 20.4% year-over-year but up 60% sequentially.
Profit decline was mainly due to increased SG&A expenses from newly acquired subsidiaries in the previous fiscal year.
Growth was driven by improved sales from acquired subsidiaries and cost reductions, with all major business segments showing progress in line with plans.
Financial highlights
Gross profit rose 23% year-over-year to ¥1,542 million, and EBITDA was ¥669 million, down 4% year-over-year but up 29% from the previous quarter.
EPS for Q1 FY2025 was ¥21.82, down from ¥32.81 in the prior year.
Comprehensive income for Q1 FY2025 was ¥225 million.
Stock sales accounted for 67% of total sales, continuing a positive trend since FY2022.
Outlook and guidance
FY2025 full-year revenue is forecast at ¥10,000 million (+15% YoY), with operating profit of ¥1,510 million (+10% YoY) and net income of ¥1,017 million (+17% YoY).
Full-year EPS forecast is ¥92.62.
Progress rates for Q1 are 26% for revenue and 25% for operating profit against full-year guidance.
Dividend payout ratio is planned at 15%, with a year-end dividend to be implemented earlier than initially scheduled.
No changes to previously announced guidance.
Latest events from Kusurinomadoguchi
- Record profit and revenue growth drive higher guidance and dividend, fueled by digital healthcare and acquisitions.5592
Q3 202613 Feb 2026 - Record profit and net income driven by recurring sales growth and capital reduction effects.5592
Q2 202614 Nov 2025 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 20258 Sep 2025 - Strong profit and revenue growth, improved financials, and robust digital healthcare outlook.5592
Q4 20258 Sep 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 20268 Sep 2025 - Record Q3 profit and revenue drive upward revision of full-year outlook and dividend.5592
Q3 20258 Sep 2025